Title |
MF59- and Al(OH)3-Adjuvanted Staphylococcus aureus (4C-Staph) Vaccines Induce Sustained Protective Humoral and Cellular Immune Responses, with a Critical Role for Effector CD4 T Cells at Low Antibody Titers
|
---|---|
Published in |
Frontiers in immunology, September 2015
|
DOI | 10.3389/fimmu.2015.00439 |
Pubmed ID | |
Authors |
Elisabetta Monaci, Francesca Mancini, Giuseppe Lofano, Marta Bacconi, Simona Tavarini, Chiara Sammicheli, Letizia Arcidiacono, Monica Giraldi, Bruno Galletti, Silvia Rossi Paccani, Antonina Torre, Maria Rita Fontana, Guido Grandi, Ennio de Gregorio, Giuliano Bensi, Emiliano Chiarot, Sandra Nuti, Fabio Bagnoli, Elisabetta Soldaini, Sylvie Bertholet |
Abstract |
Staphylococcus aureus (S. aureus) is an important opportunistic pathogen that may cause invasive life-threatening infections, like sepsis and pneumonia. Due to the increasing antibiotic resistance, the development of an effective vaccine against S. aureus is needed. Although a correlate of protection against staphylococcal diseases is not yet established, several findings suggest that both antibodies and CD4 T cells might contribute to optimal immunity. In this study, we show that adjuvanting a multivalent vaccine (4C-Staph) with MF59, an oil-in-water emulsion licensed in human vaccines, further potentiated antigen-specific IgG titers and CD4 T-cell responses compared to alum and conferred protection in the peritonitis model of S. aureus infection. Moreover, we showed that MF59- and alum-adjuvanted 4C-Staph vaccines induced persistent antigen-specific humoral and T-cell responses, and protected mice from infection up to 4 months after immunization. Furthermore, 4C-Staph formulated with MF59 was used to investigate which immune compartment is involved in vaccine-induced protection. Using CD4 T cell-depleted mice or B cell-deficient mice, we demonstrated that both T and B-cell responses contributed to 4C-Staph vaccine-mediated protective immunity. However, the role of CD4 T cells seemed more evident in the presence of low-antibody responses. This study provides preclinical data further supporting the use of the adjuvanted 4C-Staph vaccines against S. aureus diseases, and provides critical insights on the correlates of protective immunity necessary to combat this pathogen. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Switzerland | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Italy | 1 | 4% |
Unknown | 24 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 28% |
Student > Doctoral Student | 4 | 16% |
Student > Master | 3 | 12% |
Student > Bachelor | 2 | 8% |
Student > Postgraduate | 2 | 8% |
Other | 5 | 20% |
Unknown | 2 | 8% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 7 | 28% |
Medicine and Dentistry | 5 | 20% |
Biochemistry, Genetics and Molecular Biology | 4 | 16% |
Immunology and Microbiology | 3 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Other | 3 | 12% |
Unknown | 2 | 8% |